Skip to main
RAPP

RAPP Stock Forecast & Price Target

RAPP Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rapport Therapeutics is a clinical-stage biotechnology company developing small molecule medications for neurological and psychiatric conditions. The company's lead asset RAP-219, a selective AMPA modulator targeting TARPγ8, is currently in development for focal onset seizures and bipolar mania. Additionally, RAP-219 has a long half-life and potential for durability of response, addressing key concerns for patients and healthcare providers. There is a compelling "pipeline in a product" story for RAP-219, as the overlapping biology between focal onset seizures and bipolar mania indicates a broad commercial opportunity. With multiple positive data points and strong regulatory support, Rapport Therapeutics is well-positioned for success.

Bears say

Rapport Therapeutics is heavily reliant on its single drug RAP-219, which is in the early stages of development. Additionally, the company's pipeline consists mainly of discovery-stage programs, making it highly risky. The company also has a limited geographic presence, operating only in the United States, which could limit its market potential. These factors, along with the uncertainty of drug development and approval, make the outlook for Rapport Therapeutics's stock negative.

RAPP has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rapport Therapeutics Inc (RAPP) Forecast

Analysts have given RAPP a Buy based on their latest research and market trends.

According to 6 analysts, RAPP has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $60.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $60.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rapport Therapeutics Inc (RAPP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.